Boston Scientific Corp.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $16.62B | $1.93B |
| FY2022 | — | $17.57B | $928.0M |
| FY2023 | — | $19.28B | $865.0M |
| FY2024 | — | $21.77B | $414.0M |
| FY2025 | — | $24.23B | $1.97B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $16.62B | $1.93B |
| FY2022 | — | $17.57B | $928.0M |
| FY2023 | — | $19.28B | $865.0M |
| FY2024 | — | $21.77B | $414.0M |
| FY2025 | — | $24.23B | $1.97B |